Table of Contents
Journal of Cancer Research
Volume 2014 (2014), Article ID 982080, 7 pages
Research Article

Impact of Immunochemotherapy-Related Hepatic Toxicity on the Outcome of HCV-Positive Diffuse Large B-Cell Lymphoma Patients

1Department of Medical Oncology, Faculty of Medicine, Zagazig University, Sharkia 44519, Egypt
2Department of Internal Medicine, Faculty of Medicine, Zagazig University, Sharkia 44519, Egypt

Received 16 August 2014; Revised 4 November 2014; Accepted 4 November 2014; Published 30 November 2014

Academic Editor: Takahiro Yamauchi

Copyright © 2014 Fouad Abu-Taleb et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


We conducted this prospective study which included 28 de novo CD20-positive DLBCL patients to assess the clinical outcome, treatment response, and hepatic toxicity in DLBCL patients who received rituximab-CHOP as a first line treatment in relation to HCV infection status. We included 7 patients with positive HCV infection (group A) and 21 patients with negative HCV infection (group B). HCV infection was not a significant risk factor for prognosis (1-year event-free survival rates, 71.4% versus 81%, ; overall survival rates, 85.7% versus 90.5%, , for groups A and B, resp.). CR rate was 71.4% (5/7) in group A and 76.2% (16/21) in group B (). Of the 7 patients who were HCV positive, 2 (28.6%) had enzyme flare (grade 2), compared with 1 of the 21 (4.8%) patients who were HCV negative (). Two (28.6%) of the 7 positive HCV infection patients had viral reactivation (1 log10 IU/mL increase in the viral load). No patient required discontinuation of immunochemotherapy owing to hepatotoxicity in either group. In conclusion, HCV infection might not influence the clinical course in DLBCL patients who receive rituximab-CHOP. Close monitoring of hepatic function and viral load is recommended.